Blood Eosinophil Measurements in Patients With Chronic Obstructive Pulmonary Disease

Blood Eosinophil Measurements Throughout the Day in Patients With Stable Chronic Obstructive Pulmonary Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03853642

Enrollment

Registered

2019-02-25

Start date

2019-03-01

Completion date

2020-03-28

Last updated

2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

This study will assess the within-day variation of blood eosinophils in patients with Chronic Obstructive Pulmonary disease (COPD) in stable state and determine if there is a correlation between the blood eosinophils and certain clinical parameters.

Detailed description

COPD is a heterogeneous disease, resulting in different phenotypes with varying clinical and pathophysiological characteristics. One of these pathophysiological features is chronic airway inflammation which can be eosinophilic of nature. Blood eosinophils could be an accessible biomarker for this eosinophilic inflammation. Eosinophil counts can fluctuate due to their short half-life in blood and due to a diurnal rhythm. More needs to be known about this diurnal rhythm and the different confounding factors and sources of within-subject variability of this biomarker.

Interventions

OTHERBlood sampling

Blood sampling, Spirometry, Fraction exhaled Nitric Oxide

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients willing and able to give informed consent for participation in the study. * Age 18 years or older. * Diagnosis of COPD according to GOLD (Global Initiative for Chronic Obstructive Lung Disease): post-bronchodilator Tiffeneau index \<0.7), in a stable state of the disease. * A smoking history of \>10 pack-years

Exclusion criteria

* Clinical diagnosis of asthma. * Use of systemic corticosteroids (oral, intravenous or infiltration) up to six weeks before inclusion. * Pregnancy. * A recent exacerbation of COPD (\<4 weeks).

Design outcomes

Primary

Measure	Time frame	Description
Within-day within-subject level changes of blood eosinophils	12 hours	Describe the within-day within-subject levels of blood eosinophils and determine the within-day within-subject variability of blood eosinophils

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026